Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment

Findings from the Breast Cancer Surveillance Consortium

Tehillah S. Menes, Karla Kerlikowske, Shabnam Jaffer, Deborah Seger, Diana L Miglioretti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim: To examine risk factors and rates of atypical ductal hyperplasia (ADH) with and without associated breast cancer over time and tumor characteristics of breast cancer with and without associated ADH in women previously screened with mammography. Methods: Data on screeningmammograms done between 1996an d 2005 were collected from mammography registries that participate in the Breast Cancer Surveillance Consortium. Associations between age, family history of breast cancer, postmenopausal hormone treatment (HT), and final pathology result (ADH or cancer with or withoutADHin the same breast)were examined. Rates of different outcomes were calculated per examyear. Tumor characteristics of cancers with and without associated ADH were compared. Results: A total of 2,453,483 screening mammograms were associated with 1,064 biopsies with ADH, 833 breast cancers with ADH, and 8,161 cancers with no ADH. Postmenopausal HT use decreased significantly from 35% to 11% during the study period. Rates of ADH decreased from a peak of 5.5/10,000 mammograms in 1999 to 2.4/10,000 in 2005. Rates of cancer with ADH decreased from a peak of 4.3/10,000 mammograms in 2003 to 3.3/10,000 in 2005. ADH and breast cancer were significantly associated with use of postmenopausal HT. Cancer associated with ADH was of lower grade and stage and more estrogen receptor positive than cancer with no ADH. Summary: Postmenopausal HT is associated with an increased risk of ADH with or without cancer. Rates of ADH have decreased over the past decade, which may be partially explained by the significant reduction in use of postmenopausal HT.

Original languageEnglish (US)
Pages (from-to)2822-2828
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume18
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Hormones
Breast Neoplasms
Neoplasms
Therapeutics
Mammography
Estrogen Receptors
Registries

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment : Findings from the Breast Cancer Surveillance Consortium. / Menes, Tehillah S.; Kerlikowske, Karla; Jaffer, Shabnam; Seger, Deborah; Miglioretti, Diana L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 18, No. 11, 11.2009, p. 2822-2828.

Research output: Contribution to journalArticle

@article{a588e4c188ea4c6b9582819e536db850,
title = "Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: Findings from the Breast Cancer Surveillance Consortium",
abstract = "Aim: To examine risk factors and rates of atypical ductal hyperplasia (ADH) with and without associated breast cancer over time and tumor characteristics of breast cancer with and without associated ADH in women previously screened with mammography. Methods: Data on screeningmammograms done between 1996an d 2005 were collected from mammography registries that participate in the Breast Cancer Surveillance Consortium. Associations between age, family history of breast cancer, postmenopausal hormone treatment (HT), and final pathology result (ADH or cancer with or withoutADHin the same breast)were examined. Rates of different outcomes were calculated per examyear. Tumor characteristics of cancers with and without associated ADH were compared. Results: A total of 2,453,483 screening mammograms were associated with 1,064 biopsies with ADH, 833 breast cancers with ADH, and 8,161 cancers with no ADH. Postmenopausal HT use decreased significantly from 35{\%} to 11{\%} during the study period. Rates of ADH decreased from a peak of 5.5/10,000 mammograms in 1999 to 2.4/10,000 in 2005. Rates of cancer with ADH decreased from a peak of 4.3/10,000 mammograms in 2003 to 3.3/10,000 in 2005. ADH and breast cancer were significantly associated with use of postmenopausal HT. Cancer associated with ADH was of lower grade and stage and more estrogen receptor positive than cancer with no ADH. Summary: Postmenopausal HT is associated with an increased risk of ADH with or without cancer. Rates of ADH have decreased over the past decade, which may be partially explained by the significant reduction in use of postmenopausal HT.",
author = "Menes, {Tehillah S.} and Karla Kerlikowske and Shabnam Jaffer and Deborah Seger and Miglioretti, {Diana L}",
year = "2009",
month = "11",
doi = "10.1158/1055-9965.EPI-09-0745",
language = "English (US)",
volume = "18",
pages = "2822--2828",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment

T2 - Findings from the Breast Cancer Surveillance Consortium

AU - Menes, Tehillah S.

AU - Kerlikowske, Karla

AU - Jaffer, Shabnam

AU - Seger, Deborah

AU - Miglioretti, Diana L

PY - 2009/11

Y1 - 2009/11

N2 - Aim: To examine risk factors and rates of atypical ductal hyperplasia (ADH) with and without associated breast cancer over time and tumor characteristics of breast cancer with and without associated ADH in women previously screened with mammography. Methods: Data on screeningmammograms done between 1996an d 2005 were collected from mammography registries that participate in the Breast Cancer Surveillance Consortium. Associations between age, family history of breast cancer, postmenopausal hormone treatment (HT), and final pathology result (ADH or cancer with or withoutADHin the same breast)were examined. Rates of different outcomes were calculated per examyear. Tumor characteristics of cancers with and without associated ADH were compared. Results: A total of 2,453,483 screening mammograms were associated with 1,064 biopsies with ADH, 833 breast cancers with ADH, and 8,161 cancers with no ADH. Postmenopausal HT use decreased significantly from 35% to 11% during the study period. Rates of ADH decreased from a peak of 5.5/10,000 mammograms in 1999 to 2.4/10,000 in 2005. Rates of cancer with ADH decreased from a peak of 4.3/10,000 mammograms in 2003 to 3.3/10,000 in 2005. ADH and breast cancer were significantly associated with use of postmenopausal HT. Cancer associated with ADH was of lower grade and stage and more estrogen receptor positive than cancer with no ADH. Summary: Postmenopausal HT is associated with an increased risk of ADH with or without cancer. Rates of ADH have decreased over the past decade, which may be partially explained by the significant reduction in use of postmenopausal HT.

AB - Aim: To examine risk factors and rates of atypical ductal hyperplasia (ADH) with and without associated breast cancer over time and tumor characteristics of breast cancer with and without associated ADH in women previously screened with mammography. Methods: Data on screeningmammograms done between 1996an d 2005 were collected from mammography registries that participate in the Breast Cancer Surveillance Consortium. Associations between age, family history of breast cancer, postmenopausal hormone treatment (HT), and final pathology result (ADH or cancer with or withoutADHin the same breast)were examined. Rates of different outcomes were calculated per examyear. Tumor characteristics of cancers with and without associated ADH were compared. Results: A total of 2,453,483 screening mammograms were associated with 1,064 biopsies with ADH, 833 breast cancers with ADH, and 8,161 cancers with no ADH. Postmenopausal HT use decreased significantly from 35% to 11% during the study period. Rates of ADH decreased from a peak of 5.5/10,000 mammograms in 1999 to 2.4/10,000 in 2005. Rates of cancer with ADH decreased from a peak of 4.3/10,000 mammograms in 2003 to 3.3/10,000 in 2005. ADH and breast cancer were significantly associated with use of postmenopausal HT. Cancer associated with ADH was of lower grade and stage and more estrogen receptor positive than cancer with no ADH. Summary: Postmenopausal HT is associated with an increased risk of ADH with or without cancer. Rates of ADH have decreased over the past decade, which may be partially explained by the significant reduction in use of postmenopausal HT.

UR - http://www.scopus.com/inward/record.url?scp=72749084840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72749084840&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-09-0745

DO - 10.1158/1055-9965.EPI-09-0745

M3 - Article

VL - 18

SP - 2822

EP - 2828

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -